Jason P. Rhodes - May 26, 2021 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Director
Signature
/s/ Ommer Chohan, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
May 26, 2021
Transactions value $
$0
Form type
4
Date filed
5/27/2021, 08:38 PM
Next filing
Jun 11, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Award $0 +19.6K $0.00 19.6K May 26, 2021 Common Stock 19.6K $19.56 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders
F2 The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.